30 Mar 2022 by admin in UncategorizedComments Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTA C TM Molecule for the Treatment of Friedreich Ataxia
29 Mar 2022 by admin in UncategorizedComments Tempest Reports Year End 2021 Financial Results and Provides Business Update
24 Mar 2022 by admin in UncategorizedComments Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
16 Mar 2022 by admin in UncategorizedComments Innoforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies
15 Mar 2022 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
15 Mar 2022 by admin in UncategorizedComments Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
10 Mar 2022 by admin in UncategorizedComments Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
04 Mar 2022 by admin in UncategorizedComments Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
